Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm
October 18, 2017 04:22 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Oct. 18, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation
September 12, 2017 08:36 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Sept. 12, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
NeuroDerm Announces Second Quarter 2017 Financial Results
August 03, 2017 16:05 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Aug. 03, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
NeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma Corporation
August 01, 2017 16:05 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Aug. 01, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash
July 24, 2017 02:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, July 24, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
Results of NeuroDerm’s ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology
June 27, 2017 07:00 ET
|
NeuroDerm Ltd.
-Complete reduction of OFF-time to zero in 42% of patients treated for 24 hours; statistically significant and clinically meaningful reduction in OFF-time and increase in the portion of patients ON by...
NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson’s Disease and Movement Disorders
June 08, 2017 12:01 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, June 08, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
European Medicines Agency Accepts Design of NeuroDerm’s ND0612 Phase III iNDiGO Efficacy Trial
June 06, 2017 09:05 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, June 06, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders
June 05, 2017 12:01 ET
|
NeuroDerm Ltd.
-ND0612H achieved a complete reduction of OFF-time to zero in 42% of patients treated for 24 hours - - Statistically significant and clinically meaningful reduction in OFF-time and increase in the...
NeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017
May 30, 2017 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, May 30, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...